Door Pharma
ActiveDoor Pharma is a discovery phase biotech company that focuses on virus structural proteins as antiviral targets. The hypothesis underlying our work is that formation of an infectious virus requires the right interplay between viral components.
What it does
"Door Pharma is a pioneering biotech company in the health and lifetech industries, focusing on utilizing virus structural proteins as antiviral targets. The company's research is centered around the crucial role of viral structural proteins in the formation of infectious viruses. By targeting these proteins, Door Pharma aims to disrupt the interplay necessary for viral contagion. Virus structural proteins play a vital role in the structural integrity and lifecycle of viruses, making them key actors in the infectious process. Door Pharma's innovative approach seeks to identify and exploit vulnerabilities in these proteins to prevent the formation of functional viruses. Through their cutting-edge research, Door Pharma is contributing to the development of novel antiviral strategies that have the potential to revolutionize the treatment and prevention of viral infections."
Next to it in Healthcare and bio · Antiviral drug discovery biotech
- elegslabPlug and Play PnP 2026
elegslab accelerates drug discovery with AI-automated C. elegans platforms—a next-generation NAMs solution.
- Axiom TherapeuticsPlug and Play PnP 2025
AI-powered covalent drug discovery for untreatable cancers
- Vitarka TherapeuticsSOSV SOSV IndieBio NY 05
Targeting the undruggable
- Anto BiosciencesY Combinator F25
A Foundation Model for Microbial Communities.
- PaulingPlug and Play PnP 2025
Next-generation molecular simulation platform for drug discovery.
- PolybiomicsPlug and Play PnP 2025
Polybiomics enables simultaneous measurements of multiple cellular features from the same sample in real-time.
- Mahmi BioTechstars TS 2024
- Ditto BiosciencesY Combinator W26
Evolutionary intelligence for autoimmune disease